Bleomycin electroporation therapy

Drug Profile

Bleomycin electroporation therapy

Alternative Names: NeoPulse; OMS ElectroChemotherapy; SECTA therapy; Selective Electrochemical Tumor Ablation therapy

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Inovio Pharmaceuticals
  • Class Antineoplastics; Cytostatic antibiotics; Glycopeptides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Suspended Breast cancer; Head and neck cancer; Malignant melanoma
  • Discontinued Basal cell cancer; Kaposi's sarcoma; Liver cancer; Pancreatic cancer

Most Recent Events

  • 29 Sep 2017 Inovio withdraws a phase III trial in Head and neck cancer prior to enrolment in USA and European Union based on the Data Monitoring Committee's recommendation(Intratumoural) (NCT00198315)
  • 15 Mar 2016 Biomarkers information updated
  • 28 Sep 2011 OncoSec plans to conduct further clinical studies, based on positive results from clinical trials in Head and neck cancer and Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top